If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 1 - 7 of 7
Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod (COAST: CD20 and Ozanimod Sequencing Trial)
Objective
Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod
Protocol No
NEURO-CUDENVER-COAST
Categories
The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study
Objective
SetPoint System as a Pro-Remyelination Therapy for Relapsing MS
Protocol No
NEURO-SETPOINT-SPM-040
A Randomized, Open-label, Parallel-group, Non-inferiority Study Comparing Efficacy, Safety, and Tolerability of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis, Followed by Open-label Treatment W
Objective
Efficacy of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing MS
Protocol No
NEURO-NOVARTIS-RESHAPE
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing Orelabrutinib to Placebo in Patients With Primary Progressive Multiple Sclerosis
Objective
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
Protocol No
NEURO-ZENAS-PRIMROSE
A Phase 1b, Open-label, Multi-center, Randomized Study Evaluating the Safety and Tolerability of AZD0120, an Autologous CD19/BCMA Targeting Chimeric Antigen Receptor T-cells, in Adults with Refractory Relapsing or Progressing Multiple Sclerosis
Objective
AZD0120in Adults with Refractory Relapsing or Progressing MS
Protocol No
NEURO-AZ-ZENITH
Evaluating Efficacy When Transitioning From a Current Disease Modifying Therapy DMT to Ublituximab -ENHANCE
Objective
Efficacy Transitioning from a Current DMT to Ublituximab
Protocol No
NEURO-TG-ENHANCE
A Multicenter Randomized Controlled Trial of Best Available Therapy versus Autologous Hematopoietic Stem Cell Transplant for Treatment-Resistant Relapsing Multiple Sclerosis
Objective
Best Available Therapy vs Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis
Protocol No
NEURO-ITN-077I-BEAT-MS